Suppr超能文献

影响食管癌新辅助治疗 TP 方案联合 PD-1 抑制剂后客观缓解率的因素。

Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer.

机构信息

Department of Surgical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, Shaanxi, China.

Department of General Surgery, Shaanxi Provincial Cancer Hospital Affiliated to Medical College of Xi'an Jiaotong University, 309 West Yanta Road, Xi'an, 710061, Shaanxi, China.

出版信息

Sci Rep. 2023 Apr 13;13(1):6080. doi: 10.1038/s41598-023-33038-w.

Abstract

The aim of this study is to evaluate the factors affecting the objective response rate (ORR) after neoadjuvant therapy of taxol plus platinum (TP) regimen combined with programmed cell death protein-1 (PD-1) inhibitors for esophageal cancer, and establish a predictive model for forecasting ORR. According to the inclusion and exclusion criteria, consecutive esophageal cancer patients who were treated in the First Affiliated Hospital of Xi'an Jiaotong University from January 2020 to February 2022 were enrolled in this study as a training cohort, while patients who were treated in the Shaanxi Provincial Cancer Hospital Affiliated to Medical College of Xi'an Jiaotong University from January 2020 to December 2021 were enrolled as a validation cohort. All patients were treated with resectable locally advanced esophageal cancer and received neoadjuvant chemotherapy combined with immunotherapy. The ORR was defined as the sum of complete pathological response, major pathological response and partial pathological response. Logistic regression analysis was performed to determine the factors that might be related to the ORR of the patients after neoadjuvant therapy. The nomogram based on the result of regression analysis was established and verified to predict the ORR. In this study, 42 patients were included as training cohort and 53 patients were included as validation cohort. Chi-square analysis showed that neutrophil, platelet, platelet-to-lymphocytes ratio (PLR), systemic immune-inflammation index (SII), D-dimer and carcinoembryonic antigen (CEA) between ORR group and non-ORR group were significantly different. Logistic regression analysis showed that aspartate aminotransferase (AST), D-dimer and CEA were independent predictors of ORR after neoadjuvant immunotherapy. Finally, a nomogram was established based on AST, D-dimer and CEA. Internal validation and external validation revealed that the nomogram had a good ability to predict ORR after neoadjuvant immunotherapy. In conclusion, AST, D-dimer and CEA were the independent predictors of ORR after neoadjuvant immunotherapy. The nomogram based on these three indicators showed a good predictive ability.

摘要

本研究旨在评估紫杉醇联合铂类(TP)方案新辅助治疗联合程序性死亡蛋白-1(PD-1)抑制剂治疗食管癌患者的客观缓解率(ORR)的影响因素,并建立预测 ORR 的模型。根据纳入和排除标准,连续纳入 2020 年 1 月至 2022 年 2 月在西安交通大学第一附属医院接受治疗的食管癌患者作为训练队列,纳入 2020 年 1 月至 2021 年 12 月在西安交通大学医学部附属陕西省肿瘤医院接受治疗的患者作为验证队列。所有患者均为可切除局部晚期食管癌,接受新辅助化疗联合免疫治疗。ORR 定义为完全病理缓解、主要病理缓解和部分病理缓解之和。采用 logistic 回归分析确定新辅助治疗后患者 ORR 可能相关的因素。基于回归分析结果建立并验证预测 ORR 的列线图。本研究共纳入 42 例患者作为训练队列,53 例患者作为验证队列。卡方分析显示,ORR 组和非 ORR 组患者的中性粒细胞、血小板、血小板与淋巴细胞比值(PLR)、全身免疫炎症指数(SII)、D-二聚体和癌胚抗原(CEA)差异有统计学意义。Logistic 回归分析显示,天冬氨酸转氨酶(AST)、D-二聚体和 CEA 是新辅助免疫治疗后 ORR 的独立预测因素。最后,基于 AST、D-二聚体和 CEA 建立了列线图。内部验证和外部验证显示,该列线图具有良好的预测新辅助免疫治疗后 ORR 的能力。总之,AST、D-二聚体和 CEA 是新辅助免疫治疗后 ORR 的独立预测因素。基于这三个指标的列线图具有良好的预测能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d40/10102326/a923b4e224cb/41598_2023_33038_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验